Postdoctoral position in the field of cancer biology

The research group headed by Dr. Karel Souček conducting a basic and translational research in the field of cancer biology invites scientists to apply for a postdoctoral position. We wish to understand the plasticity of cancer cells in the context of tumor heterogeneity and progression. We consistently strive to publish our findings in reputable scientific journals, develop new methods and collaborate with clinicians to be able to translate our research results to practice. The key components of our daily activities include collaboration between experimentalists, medicinal chemists and clinicians, solidarity among the laboratory team and mentoring of young colleagues.


  • have received a PhD or its equivalent within the last 7 years.
  • have a publishing record – in the last three years at least two publication outputs. The applicant must be the principal author of at least one publication.
  • have experience in field molecular and cell biology, biochemistry, or biophysics
  • have experience with research projects (an advantage).
  • have excellent communication skills and the ability to collaborate with multiple teams.


  • a CV including a summary of work experience, publication activity, involvement in research grants, etc.
  • a cover letter describing motivation and previous experience
  • contact information to at least three referees
  • send applications to Karel Souček at Tato e-mailová adresa je chráněna před spamboty. Pro její zobrazení musíte mít povolen Javascript.


[1] Muresan XM, et al: Toll-like receptor 3 (TLR3) overexpression induces invasion of prostate cancer cells, whereas its activation triggers apoptosis. Am J Pathol 2022.
[2] Drapela S, et al.: High-Throughput, Parallel Flow Cytometry Screening of Hundreds of Cell Surface Antigens Using Fluorescent Barcoding. Apoptosis and Cancer: Methods and Protocol. Edited by Barcenilla H, Diaz D. New York, USA: Springer Nature, 2022.
[3] Remsik J, et al.: TGF-beta regulates Sca-1 expression and plasticity of pre-neoplastic mammary epithelial stem cells. Sci Rep 2020, 10:11396.
[4] Drapela S, et al.: The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe. Mol Oncol 2020, 14:2487-503.
[5] Remsik J, et al.: Plasticity and intratumoural heterogeneity of cell surface antigen expression in breast cancer. Br J Cancer 2018, 118:813-9.